-
Mashup Score: 0
The results of this randomised trial establish the benefit of adding short-term ADT to PBRT to prevent progression in prostate cancer. To our knowledge, these are the first such findings to show that extending salvage radiotherapy to treat the pelvic lymph nodes when combined with short-term ADT results in meaningful reductions in progression after prostatectomy in patients with prostate cancer.
Source: The LancetCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 2
Combining androgen deprivation therapy, docetaxel, and abiraterone in de novo metastatic castration-sensitive prostate cancer improved overall survival and radiographic progression-free survival with a modest increase in toxicity, mostly hypertension. This triplet therapy could become a standard of care for these patients.
Source: The LancetCategories: Expert Picks, Latest HeadlinesTweet-
PEACE-1 data on ADT + docetaxel + abiraterone/prednisone https://t.co/No2WyrVJRk
-
-
Mashup Score: 0
Prospective and detailed investigations of smoking and prostate cancer (PCa) risk and death are lacking.To investigate prediagnosis smoking habit (sta…
Source: www.sciencedirect.comCategories: Hem/Oncs, Latest HeadlinesTweet-
🚬 = increased risk of #prostatecancer death https://t.co/nEG3saGakm
-
-
Mashup Score: 0CLO22-049: Major Adverse Cardiovascular Events Risk After Androgen Deprivation Therapy Initiation is Higher for Older Patients - 2 year(s) ago
“CLO22-049: Major Adverse Cardiovascular Events Risk After Androgen Deprivation Therapy Initiation is Higher for Older Patients” published on 31 Mar 2022 by National Comprehensive Cancer Network.
Source: JNCCNCategories: Hem/Oncs, Latest HeadlinesTweet-
https://t.co/7hlZdRBJ7T
-
-
Mashup Score: 0FDA Grants Priority Review to Darolutamide/Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer - 2 year(s) ago
The FDA has accepted a supplemental new drug application and granted priority review to darolutamide plus docetaxel in patients with metastatic hormone-sensitive prostate cancer.
Source: OncLiveCategories: Hem/Oncs, Latest HeadlinesTweet-
https://t.co/uFAb3VOfqo
-
-
Mashup Score: 8Breakthrough SARS-CoV-2 Infections, Hospitalizations, and Mortality in Vaccinated Patients With Cancer - 2 year(s) ago
This cohort study examines the risk of breakthrough SARS-CoV-2 infection, hospitalizations, and mortality due to COVID-19 in vaccinated patients with cancer compared with vaccinated patients without cancer between December 2020 and November 2021.
Source: jamanetwork.comCategories: Expert Picks, Latest HeadlinesTweet-
COVID-19 😡 still causing problems, especially for patients with #cancer https://t.co/S3a2CmPyVW
-
-
Mashup Score: 0
Patients with metastatic castration-resistant prostate cancer (mCRPC) frequently receive docetaxel after they develop resistance to abiraterone or enz…
Source: www.sciencedirect.comCategories: Expert Picks, Latest HeadlinesTweet-
Pembro + docetaxel for men with #mCRPC -- will be interesting to see what the randomized trial shows. https://t.co/cGT3UtP5Sx
-
-
Mashup Score: 0Improved Survival With Enzalutamide in Patients With Metastatic Hormone-Sensitive Prostate Cancer - 2 year(s) ago
Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical Trial Updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has…
Source: Journal of Clinical OncologyCategories: Expert Picks, Latest HeadlinesTweet-
ARCHES overall survival data by @AarmstrongDuke https://t.co/TTEaDIAK9A
-
-
Mashup Score: 0Low-Grade Prostate Cancer: Time to Stop Calling It Cancer - 2 year(s) ago
Section:IntroductionProstate-specific antigen (PSA) screening for prostate cancer (PCa) remains highly controversial, largely because it is unclear whether the primary benefits of reducing rates of metastases and cancer mortality are worth the risks of overdiagnosis, overtreatment, and potential treatment-related morbidity. A major contributing factor to overdiagnosis and overtreatment is the…
Source: Journal of Clinical OncologyCategories: Expert Picks, Latest HeadlinesTweet-
🫢 Found in the #comments and #controversies section of @JCO_ASCO by @uroegg @VickersBiostats @dr_coops and others. https://t.co/uVRPsIX6M0
-
-
Mashup Score: 8Wall Street Doesn't Believe in This Target - 2 year(s) ago
A 12-year journey to bring a novel anticancer drug to the clinic solely from academia.
Source: Journal of Clinical OncologyCategories: Expert Picks, Latest HeadlinesTweet-
And an enjoyable read on #drugdevelopment @TheWistar . would be interested in hearing about the path from others who are on the other side! https://t.co/TXiCetwMNh
-
Results of the SPPORT trial #radonc - short term ADT + extending field of radiation in men with detectable #psa post prostatectomy improves outcomes #ProstateCancer @_APollack @felixfangmd https://t.co/NGiY0miFPS